Outcomes and Prognostic Analysis of Therapeutic Bronchoscopy in Non–Small Cell Lung Cancer (NSCLC) Patients With Respiratory Failure Secondary to Malignant Central Airway Obstruction (MCAO)
Pulmonary Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/pm/4702786 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Medicine, online erschienen am 20.07.2026. Verfasst von Xiuyan Liu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanjing Central Hospital, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Bronchoscopy, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Airway Obstruction. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The purpose of this study was to investigate the value of therapeutic bronchoscopy in malignant central airway obstruction (MCAO) patients secondary to non–small cell lung cancer (NSCLC), especially in those experiencing respiratory failure (RF).
Methods
This retrospective cohort study was conducted on 101 cases of NSCLC‐related MCAO patients who received therapeutic bronchoscopy from January 2018 to January 2025. Patients were classified into the RF group ( n = 39) and the non‐RF group ( n = 62) based on the presence of RF (PaO 2 /FiO 2 ≤ 300) resulting from MCAO.
Results
Therapeutic bronchoscopy achieved technical success in 93.1% of 101 patients, with no significant differences in technical success ( p = 0.521), complication rates ( p = 0.147), and short‐term or intermediate‐term efficacy between RF and non‐RF groups. Kaplan–Meier curves indicated a median survival of 16.98 months posttherapeutic bronchoscopy, with univariate analysis revealing statistically significant differences between the RF and non‐RF groups (10.46 months vs. 18.62 months, log − rank χ 2 = 4.494, p = 0.034). Multivariate Cox survival regression indicated that ECOG PS of 3–4 points (HR = 3.437, 95% CI: 1.751–6.746, p < 0.001), serum lactate dehydrogenase (LDH) ≥ 250 U/L (HR = 2.538, 95% CI: 1.328–4.852, p = 0.005), and lack of systemic antitumor treatment (HR = 3.274, 95% CI: 1.481–7.235, p = 0.003) are risk factors affecting the 2‐year survival of NSCLC‐related MCAO patients. Notably, the presence of secondary RF, the location, and the degree of airway stenosis in patients before surgery were not associated with the prognosis ( p > 0.05).
Conclusion
Therapeutic bronchoscopy is safe and effective in NSCLC patients with MCAO. This intervention should be performed promptly when airway narrowing causes RF. The ECOG PS, serum LDH level, and systemic antitumor treatment might be independent factors affecting the prognosis of MCAO patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Nanjing Central Hospital, Nanjing, Jiangsu, China.
- Department of Anesthesiology, Zhongda Hospital, Southeast University, Nanjing, China, seu.edu.bd.
- Department of Respiratory and Critical Care Medicine, Southeast University Zhongda Hospital, Nanjing, Jiangsu, China.
ORCID-Profile: Xiuyan Liu, Yukun Tao, Jing Li, Ming Ding
Zitieren
APA
Liu, X., Tao, Y., Li, J., & Ding, M. (2026). Outcomes and Prognostic Analysis of Therapeutic Bronchoscopy in Non–Small Cell Lung Cancer (NSCLC) Patients With Respiratory Failure Secondary to Malignant Central Airway Obstruction (MCAO). Pulmonary Medicine, 2026(1). https://doi.org/10.1155/pm/4702786
Vancouver
Liu X, Tao Y, Li J, Ding M. Outcomes and Prognostic Analysis of Therapeutic Bronchoscopy in Non–Small Cell Lung Cancer (NSCLC) Patients With Respiratory Failure Secondary to Malignant Central Airway Obstruction (MCAO). Pulmonary Medicine. 2026;2026(1). doi:10.1155/pm/4702786
BibTeX
@article{Liu2026,
author = {Liu, Xiuyan and Tao, Yukun and Li, Jing and Ding, Ming},
title = {Outcomes and Prognostic Analysis of Therapeutic Bronchoscopy in Non–Small Cell Lung Cancer (NSCLC) Patients With Respiratory Failure Secondary to Malignant Central Airway Obstruction (MCAO)},
journal = {Pulmonary Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/pm/4702786}
}
EUVIMED